EP2557923A4 - Behandlung von krebserkrankungen mit k-ras-mutationen - Google Patents

Behandlung von krebserkrankungen mit k-ras-mutationen

Info

Publication number
EP2557923A4
EP2557923A4 EP11769663.3A EP11769663A EP2557923A4 EP 2557923 A4 EP2557923 A4 EP 2557923A4 EP 11769663 A EP11769663 A EP 11769663A EP 2557923 A4 EP2557923 A4 EP 2557923A4
Authority
EP
European Patent Office
Prior art keywords
cancers
treatment
ras mutations
ras
mutations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11769663.3A
Other languages
English (en)
French (fr)
Other versions
EP2557923A1 (de
Inventor
Rudi Bao
Chengjung Lai
Changgeng Qian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curis Inc
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of EP2557923A1 publication Critical patent/EP2557923A1/de
Publication of EP2557923A4 publication Critical patent/EP2557923A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP11769663.3A 2010-04-16 2011-04-15 Behandlung von krebserkrankungen mit k-ras-mutationen Withdrawn EP2557923A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32491210P 2010-04-16 2010-04-16
PCT/US2011/032683 WO2011130628A1 (en) 2010-04-16 2011-04-15 Treatment of cancers having k-ras mutations

Publications (2)

Publication Number Publication Date
EP2557923A1 EP2557923A1 (de) 2013-02-20
EP2557923A4 true EP2557923A4 (de) 2013-10-23

Family

ID=44799046

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11769663.3A Withdrawn EP2557923A4 (de) 2010-04-16 2011-04-15 Behandlung von krebserkrankungen mit k-ras-mutationen

Country Status (6)

Country Link
EP (1) EP2557923A4 (de)
JP (1) JP2013525308A (de)
CN (1) CN102970868A (de)
AU (1) AU2011239537A1 (de)
CA (1) CA2795952A1 (de)
WO (1) WO2011130628A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101099926B1 (ko) * 2006-09-15 2011-12-28 화이자 프로덕츠 인코포레이티드 피리도 (2,3-ｄ) 피리미디논 화합물 및 이의 ｐｉ3 억제제로서의 용도
DK2385832T3 (en) 2009-01-08 2015-09-21 Curis Inc Phosphoinositid-3-kinase-inhibitorer med en zink-bindingsdel
SG10201602569RA (en) * 2011-04-01 2016-05-30 Curis Inc Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CA2855446C (en) * 2011-11-23 2021-04-20 Cancer Research Technology Limited Thienopyrimidine inhibitors of atypical protein kinase c
US8940742B2 (en) * 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN104513254B (zh) * 2013-09-30 2019-07-26 上海璎黎药业有限公司 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用
JP6626437B2 (ja) * 2013-10-08 2019-12-25 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ヒストンデアセチラーゼ阻害剤とＨｅｒ２阻害剤またはＰＩ３Ｋ阻害剤のいずれかの組み合わせ
EA033744B1 (ru) * 2013-11-15 2019-11-21 Oncoceutics Inc 7-бензил-4-(2-метилбензил)-2,4,6,7,8,9-гексагидроимидазо[1,2-a]пиридо[3,4-e]пиримидин-5(1h)-он, его соли и способы применения
CN103601745B (zh) * 2013-11-26 2017-01-18 大连联化化学有限公司 一种通用的乙酰氨基吡啶硼酸频哪醇酯的制备方法
SI3125898T1 (sl) * 2014-03-31 2020-07-31 The Scripps Research Institute Farmakofor za inudkcijo trail-a
CN104131034B (zh) * 2014-06-19 2017-04-05 中山大学 一种嵌合载体及其制备方法和应用
KR20170107536A (ko) 2015-01-30 2017-09-25 바스프 에스이 제초 페닐피리미딘
CA2983042C (en) * 2015-04-21 2020-01-07 Lijuan Chen Purinyl-n-hydroxyl pyrimidine formamide derivative, preparation methods and uses thereof
CN105037345B (zh) * 2015-06-09 2019-01-25 天津渤海职业技术学院 抗肿瘤化合物、其制备方法和用途
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US11020398B2 (en) 2016-08-24 2021-06-01 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
EP3521290A4 (de) 2016-09-29 2020-04-22 Daiichi Sankyo Company, Limited Kristalle von [2-(1-methyl-1h-pyrazol-4-yl)-6-(morpholin-4-yl)-9h-purin-8-yl][4-(morpholin-4-yl)piperidin-1-yl]methanon und pharmazeutisch unbedenkliches salz davon
CN118206529A (zh) 2017-09-04 2024-06-18 C4医药公司 二氢苯并咪唑酮
EP3694511A1 (de) 2017-10-13 2020-08-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Kombinationsbehandlung von pankreasarzinom
JP2021528368A (ja) * 2018-05-10 2021-10-21 ユニヴァーシティー・オブ・ルイスヴィル・リサーチ・ファウンデイション・インコーポレーテッド Ｒａｓ腫瘍性タンパク質の阻害剤、その作製方法及びその使用方法
US11234986B2 (en) 2018-09-11 2022-02-01 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
EP3898609A1 (de) 2018-12-19 2021-10-27 Shy Therapeutics LLC Mit der ras-superfamilie interagierende verbindungen zur behandlung von krebs, entzündlichen erkrankungen, rasopathien und fibrotischen erkrankungen
WO2020181232A1 (en) 2019-03-06 2020-09-10 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
IL297979A (en) 2020-05-08 2023-01-01 Halia Therapeutics Inc Inhibitors of nek7 kinase
CA3180686A1 (en) * 2020-06-04 2021-12-09 Baskaran Pillai Novel small molecules for targeted degradation of untargetable kras in cancer therapy
CN113735830A (zh) * 2021-10-11 2021-12-03 成都自豪药业有限公司 一类羟肟酸衍生物及其应用
WO2024041519A1 (zh) * 2022-08-24 2024-02-29 上海璎黎药业有限公司 一种吗啉基喹唑啉类化合物、其药物组合物及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006097449A1 (en) * 2005-03-15 2006-09-21 Menarini International Operations Luxembourg S.A. N-hydroxyamides omega-substituted with tricyclic groups as histone deacetylase inhibitors, their preparation and use in pharmaceutical formulations
WO2008076447A2 (en) * 2006-12-15 2008-06-26 Ordway Research Institute Treatments of therapy-resistant diseases comprising drug combinations
WO2009129335A2 (en) * 2008-04-15 2009-10-22 Pharmacyclics, Inc. Selective inhibitors of histone deacetylase
WO2009155659A1 (en) * 2008-06-27 2009-12-30 The University Of Queensland Combination therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101507182B1 (ko) * 2006-12-07 2015-03-30 제넨테크, 인크. 포스포이노시타이드 3-키나제 억제제 화합물 및 그의 사용 방법
RU2009134223A (ru) * 2007-02-15 2011-03-20 Новартис АГ (CH) Комбинация lbh589 с другими терапевтическими средствами, предназначенная для лечения рака
DK2385832T3 (en) * 2009-01-08 2015-09-21 Curis Inc Phosphoinositid-3-kinase-inhibitorer med en zink-bindingsdel

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006097449A1 (en) * 2005-03-15 2006-09-21 Menarini International Operations Luxembourg S.A. N-hydroxyamides omega-substituted with tricyclic groups as histone deacetylase inhibitors, their preparation and use in pharmaceutical formulations
WO2008076447A2 (en) * 2006-12-15 2008-06-26 Ordway Research Institute Treatments of therapy-resistant diseases comprising drug combinations
WO2009129335A2 (en) * 2008-04-15 2009-10-22 Pharmacyclics, Inc. Selective inhibitors of histone deacetylase
WO2009155659A1 (en) * 2008-06-27 2009-12-30 The University Of Queensland Combination therapy

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
CHIA-WEI CHOU ET AL: "HDAC Inhibition Decreases the Expression of EGFR in Colorectal Cancer Cells", PLOS ONE, vol. 6, no. 3, 25 March 2011 (2011-03-25), pages e18087, XP055078579, DOI: 10.1371/journal.pone.0018087 *
DENLINGER ET AL: "Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo", JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, MOSBY-YEAR BOOK, INC., ST. LOUIS, MO, US, vol. 130, no. 5, 1 November 2005 (2005-11-01), pages 1422 - 1429, XP005127283, ISSN: 0022-5223, DOI: 10.1016/J.JTCVS.2005.06.051 *
E LOPEZ-CRAPEZ ET AL: "Rapid and large-scale method to detect K-ras gene mutations in tumor samples", CLINICAL CHEMISTRY, 1 January 1997 (1997-01-01), pages 936 - 942, XP055078570, Retrieved from the Internet <URL:http://www.clinchem.org/content/43/6/936.full.pdf+html> [retrieved on 20130910] *
FRANKLIN WILBUR A ET AL: "KRAS Mutation Comparison of Testing Methods and Tissue Sampling Techniques in Colon Cance", JOURNAL OF MOLECULAR DIAGNOSTICS,THE, AMERICAN SOCIETY FOR INVESTIGATIVE PATHOLOGY, US, vol. 12, no. 1, 1 January 2010 (2010-01-01), pages 43 - 50, XP009168344, ISSN: 1525-1578 *
G. J. RIELY ET AL: "KRAS Mutations in Non-Small Cell Lung Cancer", PROCEEDINGS OF THE AMERICAN THORACIC SOCIETY, vol. 6, no. 2, 15 April 2009 (2009-04-15), pages 201 - 205, XP055024772, ISSN: 1546-3222, DOI: 10.1513/pats.200809-107LC *
JEET GANDHI ET AL: "Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 4, no. 2, 24 February 2009 (2009-02-24), pages E4576 - 1, XP002677508, ISSN: 1932-6203, DOI: 10.1371/JOURNAL.PONE.0004576 *
KRYPUY MICHAEL ET AL: "High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer", BMC CANCER, BIOMED CENTRAL, LONDON, GB, vol. 6, no. 1, 21 December 2006 (2006-12-21), pages 295, XP021023081, ISSN: 1471-2407, DOI: 10.1186/1471-2407-6-295 *
M A LEA ET AL: "Induction of Differentiation of Colon Cancer Cells by Combined Inhibition of Kinases and Histone Deacetylase", ANTICANCER RESEARCH, vol. 27, 1 January 2007 (2007-01-01), pages 741 - 748, XP055079030 *
N SUNAGA ET AL: "Knockdown of Oncogenic KRAS in Non-Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy", MOLECULAR CANCER THERAPEUTICS, vol. 10, 1 January 2011 (2011-01-01), pages 336 - 346, XP055079048 *
PERGOLIZZI ROBERT G ET AL: "Mutational status of codons 12 and 13 of the N- and K-ras genes in tissue and cell lines derived from primary and metastatic prostate carcinomas", CANCER INVESTIGATION, vol. 11, no. 1, 1993, pages 25 - 32, XP008164834, ISSN: 0735-7907 *
REDDY G K: "EARLY CLINICAL DATA AND POTENTIAL CLINICAL UTILITY OF NOVEL HISTONE DEACETYLASE INHIBITORS IN PROSTATE CANCER", CLINICAL PROSTATE CANCER, CANCER INFORMATION GROUP, DALLAS, TX, US, vol. 4, no. 2, 1 January 2005 (2005-01-01), pages 83 - 85, XP009079218, ISSN: 1540-0352 *
See also references of WO2011130628A1 *
WANG QINGDING ET AL: "Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3'-kinase inhibition in the KM20 human colon cancer cell line.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH JUN 2002, vol. 8, no. 6, June 2002 (2002-06-01), pages 1940 - 1947, XP055079069, ISSN: 1078-0432 *
YU X-D ET AL: "Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells", CANCER JOURNAL, JONES AND BARTLETT PUBLISHERS, US, vol. 13, no. 2, 1 March 2007 (2007-03-01), pages 105 - 113, XP008111377, ISSN: 1528-9117 *

Also Published As

Publication number Publication date
CN102970868A (zh) 2013-03-13
AU2011239537A1 (en) 2012-11-15
JP2013525308A (ja) 2013-06-20
CA2795952A1 (en) 2011-10-20
WO2011130628A1 (en) 2011-10-20
EP2557923A1 (de) 2013-02-20

Similar Documents

Publication Publication Date Title
EP2557923A4 (de) Behandlung von krebserkrankungen mit k-ras-mutationen
IL276362A (en) Cancer treatment methods
SG10201508495VA (en) Combination treatment of cancer
HK1202253A1 (en) Combination treatment of cancer
IL218575A0 (en) Treatment of cancer
HRP20170225T1 (hr) Fosfoplatini i njihova uporaba za liječenje karcinoma
HK1189272A1 (zh) 治療癌症的方法
EP2506875A4 (de) Verfahren zur behandlung von tumoren mit k-ras-mutationen
EP2640390A4 (de) Verfahren zur behandlung von karzinomen
PL388252A1 (pl) Terapia skojarzona raka jelita grubego
GB0916686D0 (en) Treatment of cancer
GB201017356D0 (en) Combination treatment of cancer
GB201017354D0 (en) Treatment of cancer
GB201002499D0 (en) Treatment of tumours
GB201121791D0 (en) Combination treatment of cancer
GB0921757D0 (en) Treatment of cancer
GB201301168D0 (en) Cancer treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20121115

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1179472

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20130924

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/19 20060101ALI20130918BHEP

Ipc: A61K 45/06 20060101ALI20130918BHEP

Ipc: A61K 31/167 20060101AFI20130918BHEP

Ipc: A61K 31/496 20060101ALI20130918BHEP

Ipc: A61K 31/4985 20060101ALI20130918BHEP

Ipc: A61K 31/16 20060101ALI20130918BHEP

Ipc: A61P 35/00 20060101ALI20130918BHEP

Ipc: A61K 31/38 20060101ALI20130918BHEP

Ipc: A61K 31/5355 20060101ALI20130918BHEP

Ipc: A61K 31/343 20060101ALI20130918BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140423

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1179472

Country of ref document: HK